nodes	percent_of_prediction	percent_of_DWPC	metapath
Sorafenib—thyroid cancer—germ cell cancer	0.409	1	CtDrD
Sorafenib—KIT—germ cell cancer	0.208	1	CbGaD
Sorafenib—UGT1A1—Etoposide—germ cell cancer	0.0137	0.0696	CbGbCtD
Sorafenib—ABCG2—Dactinomycin—germ cell cancer	0.0133	0.0678	CbGbCtD
Sorafenib—CYP3A7—Ifosfamide—germ cell cancer	0.0116	0.0592	CbGbCtD
Sorafenib—CYP3A7-CYP3A51P—Ifosfamide—germ cell cancer	0.0116	0.0592	CbGbCtD
Sorafenib—CYP2B6—Ifosfamide—germ cell cancer	0.0111	0.0563	CbGbCtD
Sorafenib—ABCC4—Methotrexate—germ cell cancer	0.00925	0.047	CbGbCtD
Sorafenib—ABCC2—Vinblastine—germ cell cancer	0.00925	0.047	CbGbCtD
Sorafenib—CYP3A5—Ifosfamide—germ cell cancer	0.00873	0.0444	CbGbCtD
Sorafenib—ABCC2—Cisplatin—germ cell cancer	0.00848	0.0431	CbGbCtD
Sorafenib—CYP2C8—Ifosfamide—germ cell cancer	0.00839	0.0427	CbGbCtD
Sorafenib—ABCC2—Etoposide—germ cell cancer	0.00833	0.0423	CbGbCtD
Sorafenib—ABCG2—Cisplatin—germ cell cancer	0.00766	0.039	CbGbCtD
Sorafenib—ABCG2—Etoposide—germ cell cancer	0.00753	0.0383	CbGbCtD
Sorafenib—CYP2C19—Ifosfamide—germ cell cancer	0.00704	0.0358	CbGbCtD
Sorafenib—CYP2C9—Ifosfamide—germ cell cancer	0.00585	0.0298	CbGbCtD
Sorafenib—ABCC2—Methotrexate—germ cell cancer	0.0055	0.028	CbGbCtD
Sorafenib—CYP2B6—Cisplatin—germ cell cancer	0.00539	0.0274	CbGbCtD
Sorafenib—ABCG2—Methotrexate—germ cell cancer	0.00498	0.0253	CbGbCtD
Sorafenib—ABCB1—Dactinomycin—germ cell cancer	0.00481	0.0245	CbGbCtD
Sorafenib—CYP3A5—Etoposide—germ cell cancer	0.00417	0.0212	CbGbCtD
Sorafenib—CYP2C8—Etoposide—germ cell cancer	0.00401	0.0204	CbGbCtD
Sorafenib—CYP3A4—Ifosfamide—germ cell cancer	0.0034	0.0173	CbGbCtD
Sorafenib—CYP1A2—Etoposide—germ cell cancer	0.00311	0.0158	CbGbCtD
Sorafenib—ABCB1—Vinblastine—germ cell cancer	0.00301	0.0153	CbGbCtD
Sorafenib—CYP2C9—Cisplatin—germ cell cancer	0.00285	0.0145	CbGbCtD
Sorafenib—CYP2D6—Vinblastine—germ cell cancer	0.00284	0.0144	CbGbCtD
Sorafenib—ABCB1—Cisplatin—germ cell cancer	0.00276	0.0141	CbGbCtD
Sorafenib—ABCB1—Etoposide—germ cell cancer	0.00272	0.0138	CbGbCtD
Sorafenib—CYP3A4—Vinblastine—germ cell cancer	0.00181	0.00918	CbGbCtD
Sorafenib—ABCB1—Methotrexate—germ cell cancer	0.00179	0.00912	CbGbCtD
Sorafenib—Regorafenib—KIT—germ cell cancer	0.00176	1	CrCbGaD
Sorafenib—CYP3A4—Etoposide—germ cell cancer	0.00163	0.00827	CbGbCtD
Sorafenib—Immune system disorder—Ifosfamide—germ cell cancer	0.000101	0.00153	CcSEcCtD
Sorafenib—Mediastinal disorder—Ifosfamide—germ cell cancer	0.000101	0.00152	CcSEcCtD
Sorafenib—Skin exfoliation—Methotrexate—germ cell cancer	0.0001	0.00152	CcSEcCtD
Sorafenib—Arrhythmia—Ifosfamide—germ cell cancer	9.98e-05	0.00151	CcSEcCtD
Sorafenib—Cough—Bleomycin—germ cell cancer	9.93e-05	0.0015	CcSEcCtD
Sorafenib—Pneumonia—Etoposide—germ cell cancer	9.88e-05	0.0015	CcSEcCtD
Sorafenib—Alopecia—Ifosfamide—germ cell cancer	9.87e-05	0.00149	CcSEcCtD
Sorafenib—Infestation NOS—Etoposide—germ cell cancer	9.83e-05	0.00149	CcSEcCtD
Sorafenib—Infestation—Etoposide—germ cell cancer	9.83e-05	0.00149	CcSEcCtD
Sorafenib—Anaemia—Dactinomycin—germ cell cancer	9.81e-05	0.00148	CcSEcCtD
Sorafenib—Mental disorder—Ifosfamide—germ cell cancer	9.79e-05	0.00148	CcSEcCtD
Sorafenib—Stevens-Johnson syndrome—Etoposide—germ cell cancer	9.74e-05	0.00147	CcSEcCtD
Sorafenib—Malnutrition—Ifosfamide—germ cell cancer	9.72e-05	0.00147	CcSEcCtD
Sorafenib—Erythema—Ifosfamide—germ cell cancer	9.72e-05	0.00147	CcSEcCtD
Sorafenib—Acute coronary syndrome—Etoposide—germ cell cancer	9.69e-05	0.00147	CcSEcCtD
Sorafenib—Myalgia—Bleomycin—germ cell cancer	9.69e-05	0.00147	CcSEcCtD
Sorafenib—Renal failure—Etoposide—germ cell cancer	9.66e-05	0.00146	CcSEcCtD
Sorafenib—Neuropathy peripheral—Etoposide—germ cell cancer	9.63e-05	0.00146	CcSEcCtD
Sorafenib—Myocardial infarction—Etoposide—germ cell cancer	9.63e-05	0.00146	CcSEcCtD
Sorafenib—Jaundice—Etoposide—germ cell cancer	9.58e-05	0.00145	CcSEcCtD
Sorafenib—Stomatitis—Etoposide—germ cell cancer	9.58e-05	0.00145	CcSEcCtD
Sorafenib—Decreased appetite—Vinblastine—germ cell cancer	9.56e-05	0.00145	CcSEcCtD
Sorafenib—Mouth ulceration—Methotrexate—germ cell cancer	9.51e-05	0.00144	CcSEcCtD
Sorafenib—Neoplasm—Methotrexate—germ cell cancer	9.51e-05	0.00144	CcSEcCtD
Sorafenib—Urinary tract disorder—Cisplatin—germ cell cancer	9.51e-05	0.00144	CcSEcCtD
Sorafenib—Leukopenia—Dactinomycin—germ cell cancer	9.5e-05	0.00144	CcSEcCtD
Sorafenib—Connective tissue disorder—Cisplatin—germ cell cancer	9.46e-05	0.00143	CcSEcCtD
Sorafenib—Urethral disorder—Cisplatin—germ cell cancer	9.44e-05	0.00143	CcSEcCtD
Sorafenib—Gynaecomastia—Methotrexate—germ cell cancer	9.42e-05	0.00142	CcSEcCtD
Sorafenib—Pain—Vinblastine—germ cell cancer	9.4e-05	0.00142	CcSEcCtD
Sorafenib—Constipation—Vinblastine—germ cell cancer	9.4e-05	0.00142	CcSEcCtD
Sorafenib—Hepatobiliary disease—Etoposide—germ cell cancer	9.29e-05	0.00141	CcSEcCtD
Sorafenib—Anaphylactic shock—Bleomycin—germ cell cancer	9.29e-05	0.0014	CcSEcCtD
Sorafenib—Infection—Bleomycin—germ cell cancer	9.22e-05	0.0014	CcSEcCtD
Sorafenib—Thrombocytopenia—Bleomycin—germ cell cancer	9.09e-05	0.00138	CcSEcCtD
Sorafenib—Myalgia—Dactinomycin—germ cell cancer	9.03e-05	0.00137	CcSEcCtD
Sorafenib—Gastrointestinal pain—Vinblastine—germ cell cancer	8.99e-05	0.00136	CcSEcCtD
Sorafenib—Anaemia—Ifosfamide—germ cell cancer	8.99e-05	0.00136	CcSEcCtD
Sorafenib—Tinnitus—Cisplatin—germ cell cancer	8.98e-05	0.00136	CcSEcCtD
Sorafenib—Flushing—Cisplatin—germ cell cancer	8.94e-05	0.00135	CcSEcCtD
Sorafenib—Cardiac disorder—Cisplatin—germ cell cancer	8.94e-05	0.00135	CcSEcCtD
Sorafenib—Angioedema—Ifosfamide—germ cell cancer	8.88e-05	0.00134	CcSEcCtD
Sorafenib—Anorexia—Bleomycin—germ cell cancer	8.85e-05	0.00134	CcSEcCtD
Sorafenib—Urinary tract disorder—Etoposide—germ cell cancer	8.71e-05	0.00132	CcSEcCtD
Sorafenib—Leukopenia—Ifosfamide—germ cell cancer	8.7e-05	0.00132	CcSEcCtD
Sorafenib—Immune system disorder—Cisplatin—germ cell cancer	8.7e-05	0.00132	CcSEcCtD
Sorafenib—Abdominal pain—Vinblastine—germ cell cancer	8.69e-05	0.00131	CcSEcCtD
Sorafenib—Mediastinal disorder—Cisplatin—germ cell cancer	8.68e-05	0.00131	CcSEcCtD
Sorafenib—Urethral disorder—Etoposide—germ cell cancer	8.65e-05	0.00131	CcSEcCtD
Sorafenib—Infection—Dactinomycin—germ cell cancer	8.6e-05	0.0013	CcSEcCtD
Sorafenib—Arrhythmia—Cisplatin—germ cell cancer	8.6e-05	0.0013	CcSEcCtD
Sorafenib—MAP3K7—testis—germ cell cancer	8.53e-05	0.00141	CbGeAlD
Sorafenib—Alopecia—Cisplatin—germ cell cancer	8.51e-05	0.00129	CcSEcCtD
Sorafenib—Hepatic failure—Methotrexate—germ cell cancer	8.5e-05	0.00129	CcSEcCtD
Sorafenib—EPHB6—adrenal gland—germ cell cancer	8.49e-05	0.0014	CbGeAlD
Sorafenib—Cough—Ifosfamide—germ cell cancer	8.49e-05	0.00128	CcSEcCtD
Sorafenib—FLT1—midbrain—germ cell cancer	8.48e-05	0.0014	CbGeAlD
Sorafenib—Thrombocytopenia—Dactinomycin—germ cell cancer	8.48e-05	0.00128	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Bleomycin—germ cell cancer	8.46e-05	0.00128	CcSEcCtD
Sorafenib—RET—endocrine gland—germ cell cancer	8.46e-05	0.00139	CbGeAlD
Sorafenib—MKNK1—head—germ cell cancer	8.45e-05	0.00139	CbGeAlD
Sorafenib—KIT—skin of body—germ cell cancer	8.44e-05	0.00139	CbGeAlD
Sorafenib—RAF1—midbrain—germ cell cancer	8.43e-05	0.00139	CbGeAlD
Sorafenib—RALBP1—female gonad—germ cell cancer	8.42e-05	0.00139	CbGeAlD
Sorafenib—Hypertension—Ifosfamide—germ cell cancer	8.4e-05	0.00127	CcSEcCtD
Sorafenib—KIT—decidua—germ cell cancer	8.39e-05	0.00138	CbGeAlD
Sorafenib—EPHB6—midbrain—germ cell cancer	8.38e-05	0.00138	CbGeAlD
Sorafenib—Malnutrition—Cisplatin—germ cell cancer	8.38e-05	0.00127	CcSEcCtD
Sorafenib—Erythema—Cisplatin—germ cell cancer	8.38e-05	0.00127	CcSEcCtD
Sorafenib—RET—head—germ cell cancer	8.35e-05	0.00137	CbGeAlD
Sorafenib—Erythema multiforme—Etoposide—germ cell cancer	8.34e-05	0.00126	CcSEcCtD
Sorafenib—FGFR1—cerebellum—germ cell cancer	8.32e-05	0.00137	CbGeAlD
Sorafenib—TIE1—brain—germ cell cancer	8.29e-05	0.00137	CbGeAlD
Sorafenib—Dyspnoea—Bleomycin—germ cell cancer	8.28e-05	0.00125	CcSEcCtD
Sorafenib—Arthralgia—Ifosfamide—germ cell cancer	8.28e-05	0.00125	CcSEcCtD
Sorafenib—Myalgia—Ifosfamide—germ cell cancer	8.28e-05	0.00125	CcSEcCtD
Sorafenib—KDR—uterus—germ cell cancer	8.28e-05	0.00136	CbGeAlD
Sorafenib—FLT1—spinal cord—germ cell cancer	8.27e-05	0.00136	CbGeAlD
Sorafenib—Renal failure acute—Methotrexate—germ cell cancer	8.27e-05	0.00125	CcSEcCtD
Sorafenib—MKNK2—testis—germ cell cancer	8.27e-05	0.00136	CbGeAlD
Sorafenib—RAF1—bone marrow—germ cell cancer	8.26e-05	0.00136	CbGeAlD
Sorafenib—Anorexia—Dactinomycin—germ cell cancer	8.25e-05	0.00125	CcSEcCtD
Sorafenib—PDGFRB—skin of body—germ cell cancer	8.25e-05	0.00136	CbGeAlD
Sorafenib—RAF1—spinal cord—germ cell cancer	8.23e-05	0.00135	CbGeAlD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Ifosfamide—germ cell cancer	8.22e-05	0.00124	CcSEcCtD
Sorafenib—HTR2C—brainstem—germ cell cancer	8.21e-05	0.00135	CbGeAlD
Sorafenib—PDGFRB—decidua—germ cell cancer	8.19e-05	0.00135	CbGeAlD
Sorafenib—Cardiac disorder—Etoposide—germ cell cancer	8.19e-05	0.00124	CcSEcCtD
Sorafenib—Flushing—Etoposide—germ cell cancer	8.19e-05	0.00124	CcSEcCtD
Sorafenib—EPHB6—spinal cord—germ cell cancer	8.18e-05	0.00135	CbGeAlD
Sorafenib—MKNK1—testis—germ cell cancer	8.17e-05	0.00134	CbGeAlD
Sorafenib—STK10—adrenal gland—germ cell cancer	8.13e-05	0.00134	CbGeAlD
Sorafenib—CSF1R—gonad—germ cell cancer	8.13e-05	0.00134	CbGeAlD
Sorafenib—MAP2K5—pituitary gland—germ cell cancer	8.13e-05	0.00134	CbGeAlD
Sorafenib—KDR—pituitary gland—germ cell cancer	8.13e-05	0.00134	CbGeAlD
Sorafenib—Hypersensitivity—Vinblastine—germ cell cancer	8.1e-05	0.00123	CcSEcCtD
Sorafenib—Dermatitis exfoliative—Methotrexate—germ cell cancer	8.1e-05	0.00122	CcSEcCtD
Sorafenib—CYP3A7—endocrine gland—germ cell cancer	8.08e-05	0.00133	CbGeAlD
Sorafenib—CSF1R—uterus—germ cell cancer	8.08e-05	0.00133	CbGeAlD
Sorafenib—Decreased appetite—Bleomycin—germ cell cancer	8.07e-05	0.00122	CcSEcCtD
Sorafenib—RET—testis—germ cell cancer	8.07e-05	0.00133	CbGeAlD
Sorafenib—Muscle spasms—Cisplatin—germ cell cancer	8.06e-05	0.00122	CcSEcCtD
Sorafenib—PDGFRA—adrenal gland—germ cell cancer	8.05e-05	0.00133	CbGeAlD
Sorafenib—TIE1—lymph node—germ cell cancer	8.01e-05	0.00132	CbGeAlD
Sorafenib—FLT1—female gonad—germ cell cancer	8.01e-05	0.00132	CbGeAlD
Sorafenib—Angiopathy—Etoposide—germ cell cancer	8e-05	0.00121	CcSEcCtD
Sorafenib—Immune system disorder—Etoposide—germ cell cancer	7.97e-05	0.00121	CcSEcCtD
Sorafenib—RAF1—female gonad—germ cell cancer	7.96e-05	0.00131	CbGeAlD
Sorafenib—BRAF—brain—germ cell cancer	7.95e-05	0.00131	CbGeAlD
Sorafenib—Mediastinal disorder—Etoposide—germ cell cancer	7.95e-05	0.0012	CcSEcCtD
Sorafenib—Pain—Bleomycin—germ cell cancer	7.94e-05	0.0012	CcSEcCtD
Sorafenib—Anaphylactic shock—Ifosfamide—germ cell cancer	7.94e-05	0.0012	CcSEcCtD
Sorafenib—CSF1R—pituitary gland—germ cell cancer	7.93e-05	0.00131	CbGeAlD
Sorafenib—EPHB6—female gonad—germ cell cancer	7.92e-05	0.0013	CbGeAlD
Sorafenib—Musculoskeletal discomfort—Dactinomycin—germ cell cancer	7.89e-05	0.00119	CcSEcCtD
Sorafenib—Asthenia—Vinblastine—germ cell cancer	7.89e-05	0.00119	CcSEcCtD
Sorafenib—Infection—Ifosfamide—germ cell cancer	7.88e-05	0.00119	CcSEcCtD
Sorafenib—MAP3K7—cerebellum—germ cell cancer	7.88e-05	0.0013	CbGeAlD
Sorafenib—STK10—bone marrow—germ cell cancer	7.87e-05	0.0013	CbGeAlD
Sorafenib—KDR—medulla oblongata—germ cell cancer	7.84e-05	0.00129	CbGeAlD
Sorafenib—MAP2K5—medulla oblongata—germ cell cancer	7.84e-05	0.00129	CbGeAlD
Sorafenib—RALBP1—endocrine gland—germ cell cancer	7.83e-05	0.00129	CbGeAlD
Sorafenib—Alopecia—Etoposide—germ cell cancer	7.8e-05	0.00118	CcSEcCtD
Sorafenib—Nervous system disorder—Ifosfamide—germ cell cancer	7.78e-05	0.00118	CcSEcCtD
Sorafenib—Thrombocytopenia—Ifosfamide—germ cell cancer	7.77e-05	0.00118	CcSEcCtD
Sorafenib—PDGFRA—spinal cord—germ cell cancer	7.75e-05	0.00128	CbGeAlD
Sorafenib—Anaemia—Cisplatin—germ cell cancer	7.75e-05	0.00117	CcSEcCtD
Sorafenib—RALBP1—head—germ cell cancer	7.73e-05	0.00127	CbGeAlD
Sorafenib—Skin disorder—Ifosfamide—germ cell cancer	7.71e-05	0.00117	CcSEcCtD
Sorafenib—BRAF—lymph node—germ cell cancer	7.68e-05	0.00127	CbGeAlD
Sorafenib—CSF1R—medulla oblongata—germ cell cancer	7.65e-05	0.00126	CbGeAlD
Sorafenib—MKNK2—cerebellum—germ cell cancer	7.64e-05	0.00126	CbGeAlD
Sorafenib—EPHX2—brain—germ cell cancer	7.6e-05	0.00125	CbGeAlD
Sorafenib—STK10—female gonad—germ cell cancer	7.58e-05	0.00125	CbGeAlD
Sorafenib—Anorexia—Ifosfamide—germ cell cancer	7.56e-05	0.00114	CcSEcCtD
Sorafenib—MKNK1—cerebellum—germ cell cancer	7.54e-05	0.00124	CbGeAlD
Sorafenib—Decreased appetite—Dactinomycin—germ cell cancer	7.53e-05	0.00114	CcSEcCtD
Sorafenib—Diarrhoea—Vinblastine—germ cell cancer	7.52e-05	0.00114	CcSEcCtD
Sorafenib—Dysgeusia—Etoposide—germ cell cancer	7.52e-05	0.00114	CcSEcCtD
Sorafenib—PDGFRA—female gonad—germ cell cancer	7.51e-05	0.00124	CbGeAlD
Sorafenib—Leukopenia—Cisplatin—germ cell cancer	7.5e-05	0.00113	CcSEcCtD
Sorafenib—RALBP1—testis—germ cell cancer	7.47e-05	0.00123	CbGeAlD
Sorafenib—Fatigue—Dactinomycin—germ cell cancer	7.47e-05	0.00113	CcSEcCtD
Sorafenib—RET—cerebellum—germ cell cancer	7.45e-05	0.00123	CbGeAlD
Sorafenib—FLT1—endocrine gland—germ cell cancer	7.45e-05	0.00123	CbGeAlD
Sorafenib—Pain—Dactinomycin—germ cell cancer	7.41e-05	0.00112	CcSEcCtD
Sorafenib—RAF1—endocrine gland—germ cell cancer	7.41e-05	0.00122	CbGeAlD
Sorafenib—Muscle spasms—Etoposide—germ cell cancer	7.38e-05	0.00112	CcSEcCtD
Sorafenib—KIT—gonad—germ cell cancer	7.38e-05	0.00122	CbGeAlD
Sorafenib—Urticaria—Bleomycin—germ cell cancer	7.38e-05	0.00112	CcSEcCtD
Sorafenib—FLT1—head—germ cell cancer	7.35e-05	0.00121	CbGeAlD
Sorafenib—EPHX2—lymph node—germ cell cancer	7.34e-05	0.00121	CbGeAlD
Sorafenib—Body temperature increased—Bleomycin—germ cell cancer	7.34e-05	0.00111	CcSEcCtD
Sorafenib—KIT—uterus—germ cell cancer	7.34e-05	0.00121	CbGeAlD
Sorafenib—RAF1—head—germ cell cancer	7.31e-05	0.0012	CbGeAlD
Sorafenib—FLT3—lymph node—germ cell cancer	7.29e-05	0.0012	CbGeAlD
Sorafenib—HTR2C—telencephalon—germ cell cancer	7.29e-05	0.0012	CbGeAlD
Sorafenib—Dizziness—Vinblastine—germ cell cancer	7.27e-05	0.0011	CcSEcCtD
Sorafenib—EPHB6—head—germ cell cancer	7.27e-05	0.0012	CbGeAlD
Sorafenib—MAP2K5—adrenal gland—germ cell cancer	7.26e-05	0.0012	CbGeAlD
Sorafenib—KDR—adrenal gland—germ cell cancer	7.26e-05	0.0012	CbGeAlD
Sorafenib—Mood swings—Methotrexate—germ cell cancer	7.24e-05	0.00109	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Ifosfamide—germ cell cancer	7.23e-05	0.00109	CcSEcCtD
Sorafenib—PDGFRB—gonad—germ cell cancer	7.21e-05	0.00119	CbGeAlD
Sorafenib—KIT—pituitary gland—germ cell cancer	7.2e-05	0.00119	CbGeAlD
Sorafenib—MAP2K5—midbrain—germ cell cancer	7.17e-05	0.00118	CbGeAlD
Sorafenib—KDR—midbrain—germ cell cancer	7.17e-05	0.00118	CbGeAlD
Sorafenib—PDGFRB—uterus—germ cell cancer	7.16e-05	0.00118	CbGeAlD
Sorafenib—Myalgia—Cisplatin—germ cell cancer	7.14e-05	0.00108	CcSEcCtD
Sorafenib—FLT1—testis—germ cell cancer	7.1e-05	0.00117	CbGeAlD
Sorafenib—Anaemia—Etoposide—germ cell cancer	7.1e-05	0.00107	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—germ cell cancer	7.09e-05	0.00107	CcSEcCtD
Sorafenib—CSF1R—adrenal gland—germ cell cancer	7.09e-05	0.00117	CbGeAlD
Sorafenib—Gastrointestinal pain—Dactinomycin—germ cell cancer	7.08e-05	0.00107	CcSEcCtD
Sorafenib—Dyspnoea—Ifosfamide—germ cell cancer	7.08e-05	0.00107	CcSEcCtD
Sorafenib—RAF1—testis—germ cell cancer	7.06e-05	0.00116	CbGeAlD
Sorafenib—STK10—endocrine gland—germ cell cancer	7.05e-05	0.00116	CbGeAlD
Sorafenib—PDGFRB—pituitary gland—germ cell cancer	7.04e-05	0.00116	CbGeAlD
Sorafenib—KDR—bone marrow—germ cell cancer	7.02e-05	0.00116	CbGeAlD
Sorafenib—EPHB6—testis—germ cell cancer	7.02e-05	0.00116	CbGeAlD
Sorafenib—CSF1R—midbrain—germ cell cancer	7e-05	0.00115	CbGeAlD
Sorafenib—MAP2K5—spinal cord—germ cell cancer	6.99e-05	0.00115	CbGeAlD
Sorafenib—KDR—spinal cord—germ cell cancer	6.99e-05	0.00115	CbGeAlD
Sorafenib—Vomiting—Vinblastine—germ cell cancer	6.99e-05	0.00106	CcSEcCtD
Sorafenib—PDGFRA—endocrine gland—germ cell cancer	6.98e-05	0.00115	CbGeAlD
Sorafenib—STK10—head—germ cell cancer	6.96e-05	0.00115	CbGeAlD
Sorafenib—KIT—medulla oblongata—germ cell cancer	6.95e-05	0.00114	CbGeAlD
Sorafenib—Breast disorder—Methotrexate—germ cell cancer	6.9e-05	0.00104	CcSEcCtD
Sorafenib—Decreased appetite—Ifosfamide—germ cell cancer	6.9e-05	0.00104	CcSEcCtD
Sorafenib—RALBP1—cerebellum—germ cell cancer	6.9e-05	0.00114	CbGeAlD
Sorafenib—PDGFRA—head—germ cell cancer	6.89e-05	0.00113	CbGeAlD
Sorafenib—Headache—Vinblastine—germ cell cancer	6.89e-05	0.00104	CcSEcCtD
Sorafenib—Toxic epidermal necrolysis—Methotrexate—germ cell cancer	6.88e-05	0.00104	CcSEcCtD
Sorafenib—Leukopenia—Etoposide—germ cell cancer	6.87e-05	0.00104	CcSEcCtD
Sorafenib—CSF1R—bone marrow—germ cell cancer	6.86e-05	0.00113	CbGeAlD
Sorafenib—FLT4—brain—germ cell cancer	6.85e-05	0.00113	CbGeAlD
Sorafenib—Gastrointestinal disorder—Ifosfamide—germ cell cancer	6.85e-05	0.00104	CcSEcCtD
Sorafenib—Body temperature increased—Dactinomycin—germ cell cancer	6.85e-05	0.00104	CcSEcCtD
Sorafenib—Abdominal pain—Dactinomycin—germ cell cancer	6.85e-05	0.00104	CcSEcCtD
Sorafenib—HTR2B—telencephalon—germ cell cancer	6.84e-05	0.00113	CbGeAlD
Sorafenib—Fatigue—Ifosfamide—germ cell cancer	6.84e-05	0.00103	CcSEcCtD
Sorafenib—Anaphylactic shock—Cisplatin—germ cell cancer	6.84e-05	0.00103	CcSEcCtD
Sorafenib—Hypersensitivity—Bleomycin—germ cell cancer	6.84e-05	0.00103	CcSEcCtD
Sorafenib—CSF1R—spinal cord—germ cell cancer	6.83e-05	0.00112	CbGeAlD
Sorafenib—Infection—Cisplatin—germ cell cancer	6.8e-05	0.00103	CcSEcCtD
Sorafenib—PDGFRB—medulla oblongata—germ cell cancer	6.79e-05	0.00112	CbGeAlD
Sorafenib—Pain—Ifosfamide—germ cell cancer	6.79e-05	0.00103	CcSEcCtD
Sorafenib—Constipation—Ifosfamide—germ cell cancer	6.79e-05	0.00103	CcSEcCtD
Sorafenib—MAP2K5—female gonad—germ cell cancer	6.77e-05	0.00111	CbGeAlD
Sorafenib—KDR—female gonad—germ cell cancer	6.77e-05	0.00111	CbGeAlD
Sorafenib—FGFR1—brain—germ cell cancer	6.76e-05	0.00111	CbGeAlD
Sorafenib—Loss of consciousness—Etoposide—germ cell cancer	6.75e-05	0.00102	CcSEcCtD
Sorafenib—STK10—testis—germ cell cancer	6.72e-05	0.00111	CbGeAlD
Sorafenib—Nervous system disorder—Cisplatin—germ cell cancer	6.71e-05	0.00101	CcSEcCtD
Sorafenib—Cough—Etoposide—germ cell cancer	6.7e-05	0.00101	CcSEcCtD
Sorafenib—Thrombocytopenia—Cisplatin—germ cell cancer	6.7e-05	0.00101	CcSEcCtD
Sorafenib—Asthenia—Bleomycin—germ cell cancer	6.66e-05	0.00101	CcSEcCtD
Sorafenib—UGT1A1—endocrine gland—germ cell cancer	6.66e-05	0.0011	CbGeAlD
Sorafenib—PDGFRA—testis—germ cell cancer	6.66e-05	0.0011	CbGeAlD
Sorafenib—Skin disorder—Cisplatin—germ cell cancer	6.65e-05	0.00101	CcSEcCtD
Sorafenib—Hypertension—Etoposide—germ cell cancer	6.63e-05	0.001	CcSEcCtD
Sorafenib—FLT4—lymph node—germ cell cancer	6.62e-05	0.00109	CbGeAlD
Sorafenib—CSF1R—female gonad—germ cell cancer	6.61e-05	0.00109	CbGeAlD
Sorafenib—Pruritus—Bleomycin—germ cell cancer	6.57e-05	0.000994	CcSEcCtD
Sorafenib—FLT1—cerebellum—germ cell cancer	6.56e-05	0.00108	CbGeAlD
Sorafenib—FGFR1—lymph node—germ cell cancer	6.53e-05	0.00108	CbGeAlD
Sorafenib—HTR2B—skin of body—germ cell cancer	6.53e-05	0.00108	CbGeAlD
Sorafenib—Nausea—Vinblastine—germ cell cancer	6.53e-05	0.000988	CcSEcCtD
Sorafenib—RAF1—cerebellum—germ cell cancer	6.52e-05	0.00107	CbGeAlD
Sorafenib—Anorexia—Cisplatin—germ cell cancer	6.52e-05	0.000986	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—germ cell cancer	6.49e-05	0.000982	CcSEcCtD
Sorafenib—Gastrointestinal pain—Ifosfamide—germ cell cancer	6.49e-05	0.000982	CcSEcCtD
Sorafenib—HTR2B—decidua—germ cell cancer	6.49e-05	0.00107	CbGeAlD
Sorafenib—EPHB6—cerebellum—germ cell cancer	6.49e-05	0.00107	CbGeAlD
Sorafenib—Pancreatitis—Methotrexate—germ cell cancer	6.47e-05	0.000979	CcSEcCtD
Sorafenib—KIT—adrenal gland—germ cell cancer	6.43e-05	0.00106	CbGeAlD
Sorafenib—MAP3K7—brain—germ cell cancer	6.4e-05	0.00105	CbGeAlD
Sorafenib—Hypersensitivity—Dactinomycin—germ cell cancer	6.38e-05	0.000965	CcSEcCtD
Sorafenib—KIT—midbrain—germ cell cancer	6.35e-05	0.00105	CbGeAlD
Sorafenib—Abdominal discomfort—Methotrexate—germ cell cancer	6.33e-05	0.000957	CcSEcCtD
Sorafenib—Urticaria—Ifosfamide—germ cell cancer	6.3e-05	0.000954	CcSEcCtD
Sorafenib—MAP2K5—endocrine gland—germ cell cancer	6.3e-05	0.00104	CbGeAlD
Sorafenib—KDR—endocrine gland—germ cell cancer	6.3e-05	0.00104	CbGeAlD
Sorafenib—PDGFRB—adrenal gland—germ cell cancer	6.28e-05	0.00103	CbGeAlD
Sorafenib—Abdominal pain—Ifosfamide—germ cell cancer	6.27e-05	0.000949	CcSEcCtD
Sorafenib—Body temperature increased—Ifosfamide—germ cell cancer	6.27e-05	0.000949	CcSEcCtD
Sorafenib—Anaphylactic shock—Etoposide—germ cell cancer	6.27e-05	0.000948	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Cisplatin—germ cell cancer	6.23e-05	0.000943	CcSEcCtD
Sorafenib—Infection—Etoposide—germ cell cancer	6.23e-05	0.000942	CcSEcCtD
Sorafenib—KIT—bone marrow—germ cell cancer	6.23e-05	0.00103	CbGeAlD
Sorafenib—KDR—head—germ cell cancer	6.22e-05	0.00102	CbGeAlD
Sorafenib—MAP2K5—head—germ cell cancer	6.22e-05	0.00102	CbGeAlD
Sorafenib—Asthenia—Dactinomycin—germ cell cancer	6.21e-05	0.00094	CcSEcCtD
Sorafenib—STK10—cerebellum—germ cell cancer	6.21e-05	0.00102	CbGeAlD
Sorafenib—PDGFRB—midbrain—germ cell cancer	6.21e-05	0.00102	CbGeAlD
Sorafenib—MKNK2—brain—germ cell cancer	6.2e-05	0.00102	CbGeAlD
Sorafenib—KIT—spinal cord—germ cell cancer	6.2e-05	0.00102	CbGeAlD
Sorafenib—MAP3K7—lymph node—germ cell cancer	6.19e-05	0.00102	CbGeAlD
Sorafenib—ABCG2—trigeminal ganglion—germ cell cancer	6.18e-05	0.00102	CbGeAlD
Sorafenib—Neutropenia—Methotrexate—germ cell cancer	6.17e-05	0.000934	CcSEcCtD
Sorafenib—PDGFRA—cerebellum—germ cell cancer	6.15e-05	0.00101	CbGeAlD
Sorafenib—CSF1R—endocrine gland—germ cell cancer	6.15e-05	0.00101	CbGeAlD
Sorafenib—Thrombocytopenia—Etoposide—germ cell cancer	6.14e-05	0.000928	CcSEcCtD
Sorafenib—MKNK1—brain—germ cell cancer	6.13e-05	0.00101	CbGeAlD
Sorafenib—Dyspnoea—Cisplatin—germ cell cancer	6.1e-05	0.000923	CcSEcCtD
Sorafenib—Skin disorder—Etoposide—germ cell cancer	6.09e-05	0.000921	CcSEcCtD
Sorafenib—Erectile dysfunction—Methotrexate—germ cell cancer	6.08e-05	0.00092	CcSEcCtD
Sorafenib—PDGFRB—bone marrow—germ cell cancer	6.08e-05	0.001	CbGeAlD
Sorafenib—CSF1R—head—germ cell cancer	6.07e-05	0.000999	CbGeAlD
Sorafenib—PDGFRB—spinal cord—germ cell cancer	6.05e-05	0.000997	CbGeAlD
Sorafenib—RET—brain—germ cell cancer	6.05e-05	0.000996	CbGeAlD
Sorafenib—MAP2K5—testis—germ cell cancer	6.01e-05	0.000989	CbGeAlD
Sorafenib—KDR—testis—germ cell cancer	6.01e-05	0.000989	CbGeAlD
Sorafenib—KIT—female gonad—germ cell cancer	6e-05	0.000988	CbGeAlD
Sorafenib—MKNK2—lymph node—germ cell cancer	5.99e-05	0.000987	CbGeAlD
Sorafenib—Anorexia—Etoposide—germ cell cancer	5.97e-05	0.000904	CcSEcCtD
Sorafenib—Decreased appetite—Cisplatin—germ cell cancer	5.95e-05	0.0009	CcSEcCtD
Sorafenib—Diarrhoea—Dactinomycin—germ cell cancer	5.93e-05	0.000896	CcSEcCtD
Sorafenib—Pneumonia—Methotrexate—germ cell cancer	5.92e-05	0.000895	CcSEcCtD
Sorafenib—MKNK1—lymph node—germ cell cancer	5.92e-05	0.000975	CbGeAlD
Sorafenib—Gastrointestinal disorder—Cisplatin—germ cell cancer	5.91e-05	0.000893	CcSEcCtD
Sorafenib—Vomiting—Bleomycin—germ cell cancer	5.9e-05	0.000893	CcSEcCtD
Sorafenib—Infestation NOS—Methotrexate—germ cell cancer	5.89e-05	0.00089	CcSEcCtD
Sorafenib—Infestation—Methotrexate—germ cell cancer	5.89e-05	0.00089	CcSEcCtD
Sorafenib—CSF1R—testis—germ cell cancer	5.86e-05	0.000965	CbGeAlD
Sorafenib—PDGFRB—female gonad—germ cell cancer	5.86e-05	0.000965	CbGeAlD
Sorafenib—Rash—Bleomycin—germ cell cancer	5.85e-05	0.000886	CcSEcCtD
Sorafenib—Pain—Cisplatin—germ cell cancer	5.85e-05	0.000885	CcSEcCtD
Sorafenib—Dermatitis—Bleomycin—germ cell cancer	5.85e-05	0.000885	CcSEcCtD
Sorafenib—Hypersensitivity—Ifosfamide—germ cell cancer	5.85e-05	0.000884	CcSEcCtD
Sorafenib—RET—lymph node—germ cell cancer	5.85e-05	0.000963	CbGeAlD
Sorafenib—Stevens-Johnson syndrome—Methotrexate—germ cell cancer	5.84e-05	0.000883	CcSEcCtD
Sorafenib—Renal failure—Methotrexate—germ cell cancer	5.79e-05	0.000875	CcSEcCtD
Sorafenib—Stomatitis—Methotrexate—germ cell cancer	5.74e-05	0.000868	CcSEcCtD
Sorafenib—HTR2C—medulla oblongata—germ cell cancer	5.72e-05	0.000943	CbGeAlD
Sorafenib—ABCC4—uterus—germ cell cancer	5.7e-05	0.000939	CbGeAlD
Sorafenib—Asthenia—Ifosfamide—germ cell cancer	5.69e-05	0.000861	CcSEcCtD
Sorafenib—HTR2B—uterus—germ cell cancer	5.67e-05	0.000934	CbGeAlD
Sorafenib—Pruritus—Ifosfamide—germ cell cancer	5.61e-05	0.000849	CcSEcCtD
Sorafenib—RALBP1—brain—germ cell cancer	5.6e-05	0.000923	CbGeAlD
Sorafenib—Dyspnoea—Etoposide—germ cell cancer	5.59e-05	0.000845	CcSEcCtD
Sorafenib—KIT—endocrine gland—germ cell cancer	5.58e-05	0.000919	CbGeAlD
Sorafenib—Hepatobiliary disease—Methotrexate—germ cell cancer	5.57e-05	0.000842	CcSEcCtD
Sorafenib—Epistaxis—Methotrexate—germ cell cancer	5.55e-05	0.00084	CcSEcCtD
Sorafenib—MAP2K5—cerebellum—germ cell cancer	5.55e-05	0.000913	CbGeAlD
Sorafenib—KDR—cerebellum—germ cell cancer	5.55e-05	0.000913	CbGeAlD
Sorafenib—Nausea—Bleomycin—germ cell cancer	5.52e-05	0.000834	CcSEcCtD
Sorafenib—KIT—head—germ cell cancer	5.51e-05	0.000907	CbGeAlD
Sorafenib—Vomiting—Dactinomycin—germ cell cancer	5.51e-05	0.000833	CcSEcCtD
Sorafenib—Rash—Dactinomycin—germ cell cancer	5.46e-05	0.000826	CcSEcCtD
Sorafenib—PDGFRB—endocrine gland—germ cell cancer	5.45e-05	0.000897	CbGeAlD
Sorafenib—Decreased appetite—Etoposide—germ cell cancer	5.45e-05	0.000824	CcSEcCtD
Sorafenib—Diarrhoea—Ifosfamide—germ cell cancer	5.43e-05	0.000821	CcSEcCtD
Sorafenib—RALBP1—lymph node—germ cell cancer	5.41e-05	0.000891	CbGeAlD
Sorafenib—CSF1R—cerebellum—germ cell cancer	5.41e-05	0.000891	CbGeAlD
Sorafenib—Gastrointestinal disorder—Etoposide—germ cell cancer	5.41e-05	0.000818	CcSEcCtD
Sorafenib—Body temperature increased—Cisplatin—germ cell cancer	5.41e-05	0.000818	CcSEcCtD
Sorafenib—Fatigue—Etoposide—germ cell cancer	5.4e-05	0.000817	CcSEcCtD
Sorafenib—PDGFRB—head—germ cell cancer	5.38e-05	0.000886	CbGeAlD
Sorafenib—Pain—Etoposide—germ cell cancer	5.36e-05	0.000811	CcSEcCtD
Sorafenib—Constipation—Etoposide—germ cell cancer	5.36e-05	0.000811	CcSEcCtD
Sorafenib—FLT1—brain—germ cell cancer	5.33e-05	0.000877	CbGeAlD
Sorafenib—KIT—testis—germ cell cancer	5.32e-05	0.000876	CbGeAlD
Sorafenib—Haemoglobin—Methotrexate—germ cell cancer	5.31e-05	0.000803	CcSEcCtD
Sorafenib—RAF1—brain—germ cell cancer	5.3e-05	0.000872	CbGeAlD
Sorafenib—Haemorrhage—Methotrexate—germ cell cancer	5.28e-05	0.000799	CcSEcCtD
Sorafenib—EPHB6—brain—germ cell cancer	5.27e-05	0.000867	CbGeAlD
Sorafenib—Dizziness—Ifosfamide—germ cell cancer	5.25e-05	0.000794	CcSEcCtD
Sorafenib—HTR2C—midbrain—germ cell cancer	5.23e-05	0.000861	CbGeAlD
Sorafenib—Urinary tract disorder—Methotrexate—germ cell cancer	5.22e-05	0.000789	CcSEcCtD
Sorafenib—PDGFRB—testis—germ cell cancer	5.2e-05	0.000856	CbGeAlD
Sorafenib—Urethral disorder—Methotrexate—germ cell cancer	5.18e-05	0.000783	CcSEcCtD
Sorafenib—FLT1—lymph node—germ cell cancer	5.15e-05	0.000848	CbGeAlD
Sorafenib—Nausea—Dactinomycin—germ cell cancer	5.14e-05	0.000778	CcSEcCtD
Sorafenib—Gastrointestinal pain—Etoposide—germ cell cancer	5.13e-05	0.000775	CcSEcCtD
Sorafenib—RAF1—lymph node—germ cell cancer	5.12e-05	0.000843	CbGeAlD
Sorafenib—HTR2C—spinal cord—germ cell cancer	5.1e-05	0.00084	CbGeAlD
Sorafenib—EPHB6—lymph node—germ cell cancer	5.09e-05	0.000838	CbGeAlD
Sorafenib—Vomiting—Ifosfamide—germ cell cancer	5.05e-05	0.000763	CcSEcCtD
Sorafenib—STK10—brain—germ cell cancer	5.04e-05	0.000831	CbGeAlD
Sorafenib—Hypersensitivity—Cisplatin—germ cell cancer	5.04e-05	0.000762	CcSEcCtD
Sorafenib—ABCC4—adrenal gland—germ cell cancer	5e-05	0.000824	CbGeAlD
Sorafenib—Rash—Ifosfamide—germ cell cancer	5e-05	0.000757	CcSEcCtD
Sorafenib—Dermatitis—Ifosfamide—germ cell cancer	5e-05	0.000756	CcSEcCtD
Sorafenib—Erythema multiforme—Methotrexate—germ cell cancer	5e-05	0.000756	CcSEcCtD
Sorafenib—PDGFRA—brain—germ cell cancer	4.99e-05	0.000822	CbGeAlD
Sorafenib—Urticaria—Etoposide—germ cell cancer	4.98e-05	0.000753	CcSEcCtD
Sorafenib—HTR2B—adrenal gland—germ cell cancer	4.98e-05	0.00082	CbGeAlD
Sorafenib—Body temperature increased—Etoposide—germ cell cancer	4.95e-05	0.000749	CcSEcCtD
Sorafenib—Abdominal pain—Etoposide—germ cell cancer	4.95e-05	0.000749	CcSEcCtD
Sorafenib—ABCB1—blood vessel—germ cell cancer	4.94e-05	0.000813	CbGeAlD
Sorafenib—Tinnitus—Methotrexate—germ cell cancer	4.93e-05	0.000745	CcSEcCtD
Sorafenib—KIT—cerebellum—germ cell cancer	4.91e-05	0.000809	CbGeAlD
Sorafenib—Asthenia—Cisplatin—germ cell cancer	4.91e-05	0.000742	CcSEcCtD
Sorafenib—Cardiac disorder—Methotrexate—germ cell cancer	4.9e-05	0.000742	CcSEcCtD
Sorafenib—STK10—lymph node—germ cell cancer	4.87e-05	0.000803	CbGeAlD
Sorafenib—ABCG2—telencephalon—germ cell cancer	4.86e-05	0.0008	CbGeAlD
Sorafenib—ABCC2—adrenal gland—germ cell cancer	4.84e-05	0.000798	CbGeAlD
Sorafenib—ABCC4—bone marrow—germ cell cancer	4.84e-05	0.000797	CbGeAlD
Sorafenib—PDGFRA—lymph node—germ cell cancer	4.83e-05	0.000794	CbGeAlD
Sorafenib—PDGFRB—cerebellum—germ cell cancer	4.8e-05	0.00079	CbGeAlD
Sorafenib—Angiopathy—Methotrexate—germ cell cancer	4.79e-05	0.000725	CcSEcCtD
Sorafenib—Immune system disorder—Methotrexate—germ cell cancer	4.77e-05	0.000722	CcSEcCtD
Sorafenib—Mediastinal disorder—Methotrexate—germ cell cancer	4.76e-05	0.00072	CcSEcCtD
Sorafenib—Nausea—Ifosfamide—germ cell cancer	4.71e-05	0.000713	CcSEcCtD
Sorafenib—Diarrhoea—Cisplatin—germ cell cancer	4.68e-05	0.000708	CcSEcCtD
Sorafenib—Alopecia—Methotrexate—germ cell cancer	4.67e-05	0.000706	CcSEcCtD
Sorafenib—ABCC4—female gonad—germ cell cancer	4.67e-05	0.000768	CbGeAlD
Sorafenib—Mental disorder—Methotrexate—germ cell cancer	4.63e-05	0.0007	CcSEcCtD
Sorafenib—Hypersensitivity—Etoposide—germ cell cancer	4.62e-05	0.000698	CcSEcCtD
Sorafenib—ABCG2—decidua—germ cell cancer	4.6e-05	0.000758	CbGeAlD
Sorafenib—Erythema—Methotrexate—germ cell cancer	4.6e-05	0.000696	CcSEcCtD
Sorafenib—Malnutrition—Methotrexate—germ cell cancer	4.6e-05	0.000696	CcSEcCtD
Sorafenib—HTR2C—head—germ cell cancer	4.54e-05	0.000747	CbGeAlD
Sorafenib—MAP2K5—brain—germ cell cancer	4.5e-05	0.000742	CbGeAlD
Sorafenib—KDR—brain—germ cell cancer	4.5e-05	0.000742	CbGeAlD
Sorafenib—Dysgeusia—Methotrexate—germ cell cancer	4.5e-05	0.000681	CcSEcCtD
Sorafenib—Asthenia—Etoposide—germ cell cancer	4.5e-05	0.00068	CcSEcCtD
Sorafenib—Pruritus—Etoposide—germ cell cancer	4.43e-05	0.000671	CcSEcCtD
Sorafenib—CSF1R—brain—germ cell cancer	4.4e-05	0.000724	CbGeAlD
Sorafenib—MAP2K5—lymph node—germ cell cancer	4.35e-05	0.000717	CbGeAlD
Sorafenib—KDR—lymph node—germ cell cancer	4.35e-05	0.000717	CbGeAlD
Sorafenib—Vomiting—Cisplatin—germ cell cancer	4.35e-05	0.000658	CcSEcCtD
Sorafenib—ABCC4—endocrine gland—germ cell cancer	4.34e-05	0.000715	CbGeAlD
Sorafenib—Rash—Cisplatin—germ cell cancer	4.31e-05	0.000652	CcSEcCtD
Sorafenib—Dermatitis—Cisplatin—germ cell cancer	4.31e-05	0.000652	CcSEcCtD
Sorafenib—Diarrhoea—Etoposide—germ cell cancer	4.29e-05	0.000649	CcSEcCtD
Sorafenib—ABCC4—head—germ cell cancer	4.28e-05	0.000705	CbGeAlD
Sorafenib—CYP2B6—skin of body—germ cell cancer	4.28e-05	0.000704	CbGeAlD
Sorafenib—HTR2B—head—germ cell cancer	4.26e-05	0.000702	CbGeAlD
Sorafenib—Anaemia—Methotrexate—germ cell cancer	4.25e-05	0.000643	CcSEcCtD
Sorafenib—CSF1R—lymph node—germ cell cancer	4.25e-05	0.000699	CbGeAlD
Sorafenib—ABCC2—endocrine gland—germ cell cancer	4.2e-05	0.000692	CbGeAlD
Sorafenib—Dizziness—Etoposide—germ cell cancer	4.14e-05	0.000627	CcSEcCtD
Sorafenib—ABCC4—testis—germ cell cancer	4.14e-05	0.000681	CbGeAlD
Sorafenib—Leukopenia—Methotrexate—germ cell cancer	4.12e-05	0.000623	CcSEcCtD
Sorafenib—CYP2C8—pituitary gland—germ cell cancer	4.07e-05	0.00067	CbGeAlD
Sorafenib—Nausea—Cisplatin—germ cell cancer	4.06e-05	0.000615	CcSEcCtD
Sorafenib—ABCG2—uterus—germ cell cancer	4.03e-05	0.000663	CbGeAlD
Sorafenib—Cough—Methotrexate—germ cell cancer	4.01e-05	0.000607	CcSEcCtD
Sorafenib—ABCC2—testis—germ cell cancer	4.01e-05	0.00066	CbGeAlD
Sorafenib—KIT—brain—germ cell cancer	3.99e-05	0.000657	CbGeAlD
Sorafenib—Vomiting—Etoposide—germ cell cancer	3.99e-05	0.000603	CcSEcCtD
Sorafenib—ABCG2—pituitary gland—germ cell cancer	3.95e-05	0.000651	CbGeAlD
Sorafenib—Rash—Etoposide—germ cell cancer	3.95e-05	0.000598	CcSEcCtD
Sorafenib—Dermatitis—Etoposide—germ cell cancer	3.95e-05	0.000597	CcSEcCtD
Sorafenib—Headache—Etoposide—germ cell cancer	3.93e-05	0.000594	CcSEcCtD
Sorafenib—Myalgia—Methotrexate—germ cell cancer	3.92e-05	0.000592	CcSEcCtD
Sorafenib—Arthralgia—Methotrexate—germ cell cancer	3.92e-05	0.000592	CcSEcCtD
Sorafenib—PDGFRB—brain—germ cell cancer	3.9e-05	0.000642	CbGeAlD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—germ cell cancer	3.89e-05	0.000588	CcSEcCtD
Sorafenib—KIT—lymph node—germ cell cancer	3.86e-05	0.000635	CbGeAlD
Sorafenib—ABCG2—medulla oblongata—germ cell cancer	3.82e-05	0.000628	CbGeAlD
Sorafenib—PDGFRB—lymph node—germ cell cancer	3.77e-05	0.00062	CbGeAlD
Sorafenib—Anaphylactic shock—Methotrexate—germ cell cancer	3.75e-05	0.000568	CcSEcCtD
Sorafenib—CYP2D6—brainstem—germ cell cancer	3.75e-05	0.000618	CbGeAlD
Sorafenib—CYP2B6—gonad—germ cell cancer	3.74e-05	0.000616	CbGeAlD
Sorafenib—Infection—Methotrexate—germ cell cancer	3.73e-05	0.000564	CcSEcCtD
Sorafenib—Nausea—Etoposide—germ cell cancer	3.72e-05	0.000563	CcSEcCtD
Sorafenib—Nervous system disorder—Methotrexate—germ cell cancer	3.68e-05	0.000557	CcSEcCtD
Sorafenib—Thrombocytopenia—Methotrexate—germ cell cancer	3.68e-05	0.000556	CcSEcCtD
Sorafenib—Skin disorder—Methotrexate—germ cell cancer	3.65e-05	0.000552	CcSEcCtD
Sorafenib—CYP2C19—endocrine gland—germ cell cancer	3.61e-05	0.000594	CbGeAlD
Sorafenib—Anorexia—Methotrexate—germ cell cancer	3.58e-05	0.000541	CcSEcCtD
Sorafenib—ABCG2—adrenal gland—germ cell cancer	3.53e-05	0.000582	CbGeAlD
Sorafenib—ABCG2—midbrain—germ cell cancer	3.49e-05	0.000574	CbGeAlD
Sorafenib—Musculoskeletal discomfort—Methotrexate—germ cell cancer	3.42e-05	0.000517	CcSEcCtD
Sorafenib—ABCG2—bone marrow—germ cell cancer	3.42e-05	0.000563	CbGeAlD
Sorafenib—ABCG2—spinal cord—germ cell cancer	3.4e-05	0.00056	CbGeAlD
Sorafenib—Dyspnoea—Methotrexate—germ cell cancer	3.35e-05	0.000506	CcSEcCtD
Sorafenib—CYP2D6—telencephalon—germ cell cancer	3.33e-05	0.000548	CbGeAlD
Sorafenib—Dyspepsia—Methotrexate—germ cell cancer	3.3e-05	0.0005	CcSEcCtD
Sorafenib—ABCG2—female gonad—germ cell cancer	3.29e-05	0.000542	CbGeAlD
Sorafenib—HTR2C—brain—germ cell cancer	3.29e-05	0.000541	CbGeAlD
Sorafenib—Decreased appetite—Methotrexate—germ cell cancer	3.26e-05	0.000494	CcSEcCtD
Sorafenib—CYP2B6—adrenal gland—germ cell cancer	3.26e-05	0.000537	CbGeAlD
Sorafenib—Gastrointestinal disorder—Methotrexate—germ cell cancer	3.24e-05	0.00049	CcSEcCtD
Sorafenib—Fatigue—Methotrexate—germ cell cancer	3.24e-05	0.00049	CcSEcCtD
Sorafenib—Pain—Methotrexate—germ cell cancer	3.21e-05	0.000486	CcSEcCtD
Sorafenib—CYP2C8—endocrine gland—germ cell cancer	3.15e-05	0.000519	CbGeAlD
Sorafenib—ABCC4—brain—germ cell cancer	3.1e-05	0.000511	CbGeAlD
Sorafenib—HTR2B—brain—germ cell cancer	3.09e-05	0.000508	CbGeAlD
Sorafenib—Gastrointestinal pain—Methotrexate—germ cell cancer	3.07e-05	0.000464	CcSEcCtD
Sorafenib—CYP3A5—female gonad—germ cell cancer	3.06e-05	0.000503	CbGeAlD
Sorafenib—ABCB1—trigeminal ganglion—germ cell cancer	3.05e-05	0.000502	CbGeAlD
Sorafenib—CYP2C8—testis—germ cell cancer	3e-05	0.000495	CbGeAlD
Sorafenib—ABCC4—lymph node—germ cell cancer	3e-05	0.000494	CbGeAlD
Sorafenib—HTR2B—lymph node—germ cell cancer	2.98e-05	0.000491	CbGeAlD
Sorafenib—Urticaria—Methotrexate—germ cell cancer	2.98e-05	0.000451	CcSEcCtD
Sorafenib—Abdominal pain—Methotrexate—germ cell cancer	2.97e-05	0.000449	CcSEcCtD
Sorafenib—Body temperature increased—Methotrexate—germ cell cancer	2.97e-05	0.000449	CcSEcCtD
Sorafenib—CYP1A2—endocrine gland—germ cell cancer	2.95e-05	0.000485	CbGeAlD
Sorafenib—ABCB1—embryo—germ cell cancer	2.94e-05	0.000485	CbGeAlD
Sorafenib—ABCG2—testis—germ cell cancer	2.92e-05	0.000481	CbGeAlD
Sorafenib—ABCC2—lymph node—germ cell cancer	2.9e-05	0.000478	CbGeAlD
Sorafenib—CYP3A5—endocrine gland—germ cell cancer	2.84e-05	0.000468	CbGeAlD
Sorafenib—CYP2B6—endocrine gland—germ cell cancer	2.83e-05	0.000465	CbGeAlD
Sorafenib—CYP2C9—endocrine gland—germ cell cancer	2.8e-05	0.000461	CbGeAlD
Sorafenib—CYP2B6—head—germ cell cancer	2.79e-05	0.000459	CbGeAlD
Sorafenib—Hypersensitivity—Methotrexate—germ cell cancer	2.77e-05	0.000418	CcSEcCtD
Sorafenib—ABCG2—cerebellum—germ cell cancer	2.7e-05	0.000444	CbGeAlD
Sorafenib—CYP2B6—testis—germ cell cancer	2.7e-05	0.000444	CbGeAlD
Sorafenib—Asthenia—Methotrexate—germ cell cancer	2.69e-05	0.000407	CcSEcCtD
Sorafenib—Pruritus—Methotrexate—germ cell cancer	2.66e-05	0.000402	CcSEcCtD
Sorafenib—ABCB1—retina—germ cell cancer	2.6e-05	0.000429	CbGeAlD
Sorafenib—Diarrhoea—Methotrexate—germ cell cancer	2.57e-05	0.000389	CcSEcCtD
Sorafenib—Dizziness—Methotrexate—germ cell cancer	2.48e-05	0.000375	CcSEcCtD
Sorafenib—ABCB1—telencephalon—germ cell cancer	2.39e-05	0.000394	CbGeAlD
Sorafenib—Vomiting—Methotrexate—germ cell cancer	2.39e-05	0.000361	CcSEcCtD
Sorafenib—Rash—Methotrexate—germ cell cancer	2.37e-05	0.000358	CcSEcCtD
Sorafenib—Dermatitis—Methotrexate—germ cell cancer	2.36e-05	0.000358	CcSEcCtD
Sorafenib—Headache—Methotrexate—germ cell cancer	2.35e-05	0.000356	CcSEcCtD
Sorafenib—ABCB1—decidua—germ cell cancer	2.27e-05	0.000374	CbGeAlD
Sorafenib—CYP2D6—female gonad—germ cell cancer	2.26e-05	0.000372	CbGeAlD
Sorafenib—CYP2C8—brain—germ cell cancer	2.25e-05	0.000371	CbGeAlD
Sorafenib—Nausea—Methotrexate—germ cell cancer	2.23e-05	0.000337	CcSEcCtD
Sorafenib—ABCG2—brain—germ cell cancer	2.19e-05	0.000361	CbGeAlD
Sorafenib—CYP3A4—endocrine gland—germ cell cancer	2.13e-05	0.000351	CbGeAlD
Sorafenib—ABCG2—lymph node—germ cell cancer	2.12e-05	0.000349	CbGeAlD
Sorafenib—CYP2D6—endocrine gland—germ cell cancer	2.1e-05	0.000346	CbGeAlD
Sorafenib—CYP2D6—head—germ cell cancer	2.07e-05	0.000341	CbGeAlD
Sorafenib—CYP2B6—brain—germ cell cancer	2.02e-05	0.000333	CbGeAlD
Sorafenib—CYP2D6—testis—germ cell cancer	2e-05	0.00033	CbGeAlD
Sorafenib—ABCB1—gonad—germ cell cancer	2e-05	0.000329	CbGeAlD
Sorafenib—ABCB1—uterus—germ cell cancer	1.99e-05	0.000327	CbGeAlD
Sorafenib—ABCB1—pituitary gland—germ cell cancer	1.95e-05	0.000321	CbGeAlD
Sorafenib—ABCB1—medulla oblongata—germ cell cancer	1.88e-05	0.00031	CbGeAlD
Sorafenib—CYP2D6—cerebellum—germ cell cancer	1.85e-05	0.000305	CbGeAlD
Sorafenib—ABCB1—adrenal gland—germ cell cancer	1.74e-05	0.000287	CbGeAlD
Sorafenib—ABCB1—midbrain—germ cell cancer	1.72e-05	0.000283	CbGeAlD
Sorafenib—ABCB1—bone marrow—germ cell cancer	1.69e-05	0.000277	CbGeAlD
Sorafenib—ABCB1—spinal cord—germ cell cancer	1.68e-05	0.000276	CbGeAlD
Sorafenib—ABCB1—female gonad—germ cell cancer	1.62e-05	0.000267	CbGeAlD
Sorafenib—ABCB1—endocrine gland—germ cell cancer	1.51e-05	0.000249	CbGeAlD
Sorafenib—CYP2D6—brain—germ cell cancer	1.5e-05	0.000247	CbGeAlD
Sorafenib—ABCB1—head—germ cell cancer	1.49e-05	0.000246	CbGeAlD
Sorafenib—ABCB1—testis—germ cell cancer	1.44e-05	0.000237	CbGeAlD
Sorafenib—ABCB1—cerebellum—germ cell cancer	1.33e-05	0.000219	CbGeAlD
Sorafenib—ABCB1—brain—germ cell cancer	1.08e-05	0.000178	CbGeAlD
Sorafenib—ABCB1—lymph node—germ cell cancer	1.04e-05	0.000172	CbGeAlD
Sorafenib—PDGFRA—Signaling Pathways—OXT—germ cell cancer	6.34e-06	0.00011	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—FGF4—germ cell cancer	6.34e-06	0.00011	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—CRABP1—germ cell cancer	6.33e-06	0.00011	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—AVP—germ cell cancer	6.32e-06	0.000109	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—CRABP1—germ cell cancer	6.28e-06	0.000109	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—FGF4—germ cell cancer	6.28e-06	0.000109	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—H2AFZ—germ cell cancer	6.21e-06	0.000108	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—KITLG—germ cell cancer	6.21e-06	0.000108	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—KIT—germ cell cancer	6.21e-06	0.000108	CbGpPWpGaD
Sorafenib—RAF1—Adaptive Immune System—KIT—germ cell cancer	6.21e-06	0.000108	CbGpPWpGaD
Sorafenib—RAF1—Disease—FGF4—germ cell cancer	6.2e-06	0.000107	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—KITLG—germ cell cancer	6.19e-06	0.000107	CbGpPWpGaD
Sorafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—germ cell cancer	6.15e-06	0.000107	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—CRABP1—germ cell cancer	6.14e-06	0.000106	CbGpPWpGaD
Sorafenib—FGFR1—Signaling by NGF—HRAS—germ cell cancer	6.12e-06	0.000106	CbGpPWpGaD
Sorafenib—CDK7—Cell Cycle—TP53—germ cell cancer	6.11e-06	0.000106	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling by NGF—HRAS—germ cell cancer	6.1e-06	0.000106	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—AVP—germ cell cancer	6.07e-06	0.000105	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—KITLG—germ cell cancer	6.05e-06	0.000105	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—FGFR3—germ cell cancer	5.98e-06	0.000104	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—AVP—germ cell cancer	5.92e-06	0.000103	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—AVP—germ cell cancer	5.9e-06	0.000102	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—SLC2A3—germ cell cancer	5.78e-06	0.0001	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—KITLG—germ cell cancer	5.72e-06	9.9e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—FGF4—germ cell cancer	5.71e-06	9.9e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—FGF4—germ cell cancer	5.71e-06	9.9e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—OXT—germ cell cancer	5.71e-06	9.89e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—SLC22A3—germ cell cancer	5.69e-06	9.87e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—H2AFZ—germ cell cancer	5.66e-06	9.8e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—SLC2A3—germ cell cancer	5.65e-06	9.79e-05	CbGpPWpGaD
Sorafenib—HTR2C—GPCR downstream signaling—AVP—germ cell cancer	5.61e-06	9.72e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—H2AFZ—germ cell cancer	5.6e-06	9.71e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—SLC22A3—germ cell cancer	5.57e-06	9.64e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—H2AFZ—germ cell cancer	5.54e-06	9.59e-05	CbGpPWpGaD
Sorafenib—FGFR1—Axon guidance—HRAS—germ cell cancer	5.53e-06	9.59e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—KITLG—germ cell cancer	5.52e-06	9.56e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling by NGF—HRAS—germ cell cancer	5.5e-06	9.52e-05	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—KIT—germ cell cancer	5.49e-06	9.52e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—FGFR3—germ cell cancer	5.47e-06	9.48e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—OXT—germ cell cancer	5.44e-06	9.43e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—FGF4—germ cell cancer	5.42e-06	9.39e-05	CbGpPWpGaD
Sorafenib—MKNK1—Disease—MYC—germ cell cancer	5.42e-06	9.39e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—FGF4—germ cell cancer	5.41e-06	9.37e-05	CbGpPWpGaD
Sorafenib—KIT—Immune System—FGFR3—germ cell cancer	5.4e-06	9.35e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—FGFR3—germ cell cancer	5.4e-06	9.35e-05	CbGpPWpGaD
Sorafenib—KDR—Developmental Biology—HRAS—germ cell cancer	5.37e-06	9.3e-05	CbGpPWpGaD
Sorafenib—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—germ cell cancer	5.31e-06	9.2e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—KITLG—germ cell cancer	5.2e-06	9.02e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—KITLG—germ cell cancer	5.16e-06	8.93e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—FGFR3—germ cell cancer	5.12e-06	8.87e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—FGFR3—germ cell cancer	5.11e-06	8.85e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—H2AFZ—germ cell cancer	5.1e-06	8.84e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—H2AFZ—germ cell cancer	5.1e-06	8.84e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—AVP—germ cell cancer	5.1e-06	8.83e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—KITLG—germ cell cancer	5.09e-06	8.83e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—AVP—germ cell cancer	5.09e-06	8.81e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—OXT—germ cell cancer	5.09e-06	8.81e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—AVP—germ cell cancer	5.04e-06	8.73e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—KIT—germ cell cancer	5.02e-06	8.71e-05	CbGpPWpGaD
Sorafenib—RAF1—Neuronal System—HRAS—germ cell cancer	5e-06	8.66e-05	CbGpPWpGaD
Sorafenib—RAF1—Cytokine Signaling in Immune system—HRAS—germ cell cancer	4.98e-06	8.63e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—FGFR3—germ cell cancer	4.98e-06	8.63e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—KIT—germ cell cancer	4.95e-06	8.58e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling by NGF—HRAS—germ cell cancer	4.9e-06	8.49e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—SLC2A3—germ cell cancer	4.89e-06	8.48e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—FGF4—germ cell cancer	4.87e-06	8.44e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—H2AFZ—germ cell cancer	4.84e-06	8.39e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—H2AFZ—germ cell cancer	4.83e-06	8.37e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—SLC22A3—germ cell cancer	4.82e-06	8.35e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—FGFR3—germ cell cancer	4.73e-06	8.19e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—FGFR3—germ cell cancer	4.72e-06	8.17e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—KIT—germ cell cancer	4.7e-06	8.15e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—KITLG—germ cell cancer	4.69e-06	8.13e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—KITLG—germ cell cancer	4.69e-06	8.13e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—KIT—germ cell cancer	4.69e-06	8.12e-05	CbGpPWpGaD
Sorafenib—RALBP1—Signaling Pathways—MYC—germ cell cancer	4.65e-06	8.06e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—FGF4—germ cell cancer	4.65e-06	8.05e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—CRABP1—germ cell cancer	4.64e-06	8.04e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—FGFR3—germ cell cancer	4.62e-06	8e-05	CbGpPWpGaD
Sorafenib—MAPK11—Developmental Biology—HRAS—germ cell cancer	4.62e-06	8e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—FGFR3—germ cell cancer	4.6e-06	7.97e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—AVP—germ cell cancer	4.59e-06	7.95e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—AVP—germ cell cancer	4.59e-06	7.95e-05	CbGpPWpGaD
Sorafenib—FLT4—Signaling Pathways—MYC—germ cell cancer	4.58e-06	7.93e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—CRABP1—germ cell cancer	4.54e-06	7.86e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—FGFR3—germ cell cancer	4.5e-06	7.79e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—KITLG—germ cell cancer	4.45e-06	7.72e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—KITLG—germ cell cancer	4.44e-06	7.7e-05	CbGpPWpGaD
Sorafenib—RAF1—Axon guidance—HRAS—germ cell cancer	4.43e-06	7.68e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—OXT—germ cell cancer	4.39e-06	7.61e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—SLC2A3—germ cell cancer	4.37e-06	7.57e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—AVP—germ cell cancer	4.35e-06	7.54e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—H2AFZ—germ cell cancer	4.35e-06	7.54e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—AVP—germ cell cancer	4.34e-06	7.52e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—FGF4—germ cell cancer	4.34e-06	7.52e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—KIT—germ cell cancer	4.34e-06	7.52e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—KIT—germ cell cancer	4.33e-06	7.5e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—SLC22A3—germ cell cancer	4.3e-06	7.46e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—SLC2A3—germ cell cancer	4.26e-06	7.39e-05	CbGpPWpGaD
Sorafenib—MKNK1—Disease—HRAS—germ cell cancer	4.25e-06	7.37e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—FGFR3—germ cell cancer	4.25e-06	7.36e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—KIT—germ cell cancer	4.24e-06	7.34e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—KIT—germ cell cancer	4.22e-06	7.32e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—SLC22A3—germ cell cancer	4.2e-06	7.28e-05	CbGpPWpGaD
Sorafenib—ABCB1—Transmembrane transport of small molecules—AVP—germ cell cancer	4.2e-06	7.27e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—H2AFZ—germ cell cancer	4.15e-06	7.19e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—KIT—germ cell cancer	4.13e-06	7.16e-05	CbGpPWpGaD
Sorafenib—CDK7—Gene Expression—MYC—germ cell cancer	4.11e-06	7.12e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—FGFR3—germ cell cancer	4.1e-06	7.11e-05	CbGpPWpGaD
Sorafenib—MAPK11—Innate Immune System—HRAS—germ cell cancer	4.08e-06	7.06e-05	CbGpPWpGaD
Sorafenib—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—germ cell cancer	4.06e-06	7.04e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—SLC2A3—germ cell cancer	4.02e-06	6.96e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—KITLG—germ cell cancer	4e-06	6.93e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—SLC2A3—germ cell cancer	3.98e-06	6.9e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—SLC22A3—germ cell cancer	3.96e-06	6.86e-05	CbGpPWpGaD
Sorafenib—FGFR1—Developmental Biology—HRAS—germ cell cancer	3.95e-06	6.84e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—CRABP1—germ cell cancer	3.93e-06	6.81e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—SLC22A3—germ cell cancer	3.92e-06	6.8e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—AVP—germ cell cancer	3.91e-06	6.78e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—KIT—germ cell cancer	3.9e-06	6.76e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—H2AFZ—germ cell cancer	3.88e-06	6.72e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—FGFR3—germ cell cancer	3.87e-06	6.7e-05	CbGpPWpGaD
Sorafenib—ABCC4—Hemostasis—TP53—germ cell cancer	3.86e-06	6.69e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—FGFR3—germ cell cancer	3.83e-06	6.64e-05	CbGpPWpGaD
Sorafenib—RALBP1—Signaling Pathways—TP53—germ cell cancer	3.82e-06	6.62e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—KITLG—germ cell cancer	3.82e-06	6.61e-05	CbGpPWpGaD
Sorafenib—CDK7—Disease—MYC—germ cell cancer	3.82e-06	6.61e-05	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—MYC—germ cell cancer	3.79e-06	6.57e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—FGFR3—germ cell cancer	3.79e-06	6.56e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—KIT—germ cell cancer	3.76e-06	6.52e-05	CbGpPWpGaD
Sorafenib—FLT4—Signaling Pathways—TP53—germ cell cancer	3.76e-06	6.51e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—FGF4—germ cell cancer	3.75e-06	6.49e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—AVP—germ cell cancer	3.73e-06	6.46e-05	CbGpPWpGaD
Sorafenib—ABCC4—Hemostasis—HRAS—germ cell cancer	3.69e-06	6.39e-05	CbGpPWpGaD
Sorafenib—KIT—Innate Immune System—HRAS—germ cell cancer	3.68e-06	6.37e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Innate Immune System—HRAS—germ cell cancer	3.68e-06	6.37e-05	CbGpPWpGaD
Sorafenib—RALBP1—Signaling Pathways—HRAS—germ cell cancer	3.65e-06	6.33e-05	CbGpPWpGaD
Sorafenib—FLT4—Signaling Pathways—HRAS—germ cell cancer	3.6e-06	6.23e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—KITLG—germ cell cancer	3.57e-06	6.18e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—KIT—germ cell cancer	3.55e-06	6.15e-05	CbGpPWpGaD
Sorafenib—KIT—Adaptive Immune System—HRAS—germ cell cancer	3.53e-06	6.11e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Adaptive Immune System—HRAS—germ cell cancer	3.53e-06	6.11e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—KIT—germ cell cancer	3.52e-06	6.1e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—CRABP1—germ cell cancer	3.51e-06	6.08e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—FGFR3—germ cell cancer	3.49e-06	6.04e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—FGFR3—germ cell cancer	3.49e-06	6.04e-05	CbGpPWpGaD
Sorafenib—FGFR1—Innate Immune System—HRAS—germ cell cancer	3.49e-06	6.04e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—AVP—germ cell cancer	3.49e-06	6.04e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Innate Immune System—HRAS—germ cell cancer	3.48e-06	6.03e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—KIT—germ cell cancer	3.48e-06	6.02e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—CRABP1—germ cell cancer	3.42e-06	5.93e-05	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—MYC—germ cell cancer	3.42e-06	5.92e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—SLC2A3—germ cell cancer	3.4e-06	5.9e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—SLC22A3—germ cell cancer	3.35e-06	5.81e-05	CbGpPWpGaD
Sorafenib—FGFR1—Adaptive Immune System—HRAS—germ cell cancer	3.35e-06	5.8e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—H2AFZ—germ cell cancer	3.35e-06	5.8e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Adaptive Immune System—HRAS—germ cell cancer	3.34e-06	5.79e-05	CbGpPWpGaD
Sorafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—germ cell cancer	3.34e-06	5.78e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—FGFR3—germ cell cancer	3.31e-06	5.74e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—FGFR3—germ cell cancer	3.3e-06	5.72e-05	CbGpPWpGaD
Sorafenib—RAF1—Hemostasis—TP53—germ cell cancer	3.24e-06	5.62e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—CRABP1—germ cell cancer	3.23e-06	5.59e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—KIT—germ cell cancer	3.2e-06	5.55e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—CRABP1—germ cell cancer	3.2e-06	5.54e-05	CbGpPWpGaD
Sorafenib—RAF1—Developmental Biology—HRAS—germ cell cancer	3.16e-06	5.48e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Innate Immune System—HRAS—germ cell cancer	3.13e-06	5.43e-05	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—TP53—germ cell cancer	3.12e-06	5.4e-05	CbGpPWpGaD
Sorafenib—RAF1—Hemostasis—HRAS—germ cell cancer	3.1e-06	5.38e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—KITLG—germ cell cancer	3.08e-06	5.34e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—KIT—germ cell cancer	3.04e-06	5.27e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—KIT—germ cell cancer	3.03e-06	5.25e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—AVP—germ cell cancer	3.01e-06	5.21e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Adaptive Immune System—HRAS—germ cell cancer	3.01e-06	5.21e-05	CbGpPWpGaD
Sorafenib—MAPK11—Gene Expression—MYC—germ cell cancer	3.01e-06	5.21e-05	CbGpPWpGaD
Sorafenib—CDK7—Disease—HRAS—germ cell cancer	3e-06	5.19e-05	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—HRAS—germ cell cancer	2.98e-06	5.16e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—FGFR3—germ cell cancer	2.97e-06	5.15e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—FGFR3—germ cell cancer	2.84e-06	4.92e-05	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—TP53—germ cell cancer	2.81e-06	4.86e-05	CbGpPWpGaD
Sorafenib—RAF1—Innate Immune System—HRAS—germ cell cancer	2.79e-06	4.84e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—MYC—germ cell cancer	2.76e-06	4.79e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—CRABP1—germ cell cancer	2.73e-06	4.74e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—KIT—germ cell cancer	2.73e-06	4.73e-05	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—HRAS—germ cell cancer	2.68e-06	4.65e-05	CbGpPWpGaD
Sorafenib—RAF1—Adaptive Immune System—HRAS—germ cell cancer	2.68e-06	4.65e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—FGFR3—germ cell cancer	2.65e-06	4.59e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—SLC2A3—germ cell cancer	2.63e-06	4.55e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—KIT—germ cell cancer	2.6e-06	4.51e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—SLC22A3—germ cell cancer	2.59e-06	4.48e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—MYC—germ cell cancer	2.52e-06	4.36e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—KIT—germ cell cancer	2.43e-06	4.22e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—MYC—germ cell cancer	2.39e-06	4.14e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—MYC—germ cell cancer	2.38e-06	4.13e-05	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—HRAS—germ cell cancer	2.37e-06	4.11e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—MYC—germ cell cancer	2.33e-06	4.04e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—FGFR3—germ cell cancer	2.29e-06	3.97e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—MYC—germ cell cancer	2.27e-06	3.94e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—HRAS—germ cell cancer	2.17e-06	3.76e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—MYC—germ cell cancer	2.15e-06	3.72e-05	CbGpPWpGaD
Sorafenib—KIT—Immune System—HRAS—germ cell cancer	2.14e-06	3.71e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—HRAS—germ cell cancer	2.14e-06	3.71e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CRABP1—germ cell cancer	2.11e-06	3.65e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—KIT—germ cell cancer	2.1e-06	3.64e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—HRAS—germ cell cancer	2.03e-06	3.52e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—HRAS—germ cell cancer	2.03e-06	3.51e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—HRAS—germ cell cancer	1.98e-06	3.42e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—MYC—germ cell cancer	1.95e-06	3.39e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—MYC—germ cell cancer	1.94e-06	3.35e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—TP53—germ cell cancer	1.92e-06	3.32e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—MYC—germ cell cancer	1.91e-06	3.31e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—HRAS—germ cell cancer	1.91e-06	3.3e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—HRAS—germ cell cancer	1.88e-06	3.25e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—HRAS—germ cell cancer	1.87e-06	3.24e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—TP53—germ cell cancer	1.87e-06	3.23e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—HRAS—germ cell cancer	1.83e-06	3.17e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—HRAS—germ cell cancer	1.83e-06	3.16e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—HRAS—germ cell cancer	1.78e-06	3.09e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—HRAS—germ cell cancer	1.78e-06	3.09e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—MYC—germ cell cancer	1.76e-06	3.05e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—MYC—germ cell cancer	1.76e-06	3.05e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—HRAS—germ cell cancer	1.69e-06	2.92e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—MYC—germ cell cancer	1.67e-06	2.9e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—MYC—germ cell cancer	1.67e-06	2.89e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—HRAS—germ cell cancer	1.63e-06	2.82e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—TP53—germ cell cancer	1.6e-06	2.78e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—TP53—germ cell cancer	1.59e-06	2.75e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—HRAS—germ cell cancer	1.54e-06	2.66e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—HRAS—germ cell cancer	1.53e-06	2.66e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—HRAS—germ cell cancer	1.52e-06	2.63e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—MYC—germ cell cancer	1.5e-06	2.6e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—HRAS—germ cell cancer	1.5e-06	2.6e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—TP53—germ cell cancer	1.45e-06	2.51e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—TP53—germ cell cancer	1.45e-06	2.51e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—MYC—germ cell cancer	1.43e-06	2.48e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—HRAS—germ cell cancer	1.38e-06	2.4e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—HRAS—germ cell cancer	1.38e-06	2.4e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—TP53—germ cell cancer	1.37e-06	2.38e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—TP53—germ cell cancer	1.37e-06	2.37e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—MYC—germ cell cancer	1.34e-06	2.32e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—HRAS—germ cell cancer	1.31e-06	2.28e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—HRAS—germ cell cancer	1.31e-06	2.27e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—TP53—germ cell cancer	1.23e-06	2.14e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—HRAS—germ cell cancer	1.18e-06	2.05e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—TP53—germ cell cancer	1.18e-06	2.04e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—MYC—germ cell cancer	1.16e-06	2e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—HRAS—germ cell cancer	1.13e-06	1.95e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—TP53—germ cell cancer	1.1e-06	1.91e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—HRAS—germ cell cancer	1.05e-06	1.82e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—TP53—germ cell cancer	9.5e-07	1.65e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—HRAS—germ cell cancer	9.08e-07	1.57e-05	CbGpPWpGaD
